NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis $11.56 -0.38 (-3.18%) (As of 02:37 PM ET) Add Compare Share Share Today's Range$11.51▼$12.0150-Day Range$11.10▼$13.2452-Week Range$10.00▼$24.40Volume4,307 shsAverage Volume42,843 shsMarket Capitalization$81.38 millionP/E RatioN/ADividend YieldN/APrice Target$29.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cidara Therapeutics alerts: Email Address Cidara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside155.7% Upside$29.67 Price TargetShort InterestHealthy1.24% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.25Based on 12 Articles This WeekInsider TradingSelling Shares$10,755 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($12.06) to ($12.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.25 out of 5 starsMedical Sector152nd out of 927 stocksBiological Products, Except Diagnostic Industry19th out of 154 stocks 3.6 Analyst's Opinion Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCidara Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cidara Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.24% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently decreased by 23.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cidara Therapeutics is -0.85. Previous Next 2.4 News and Social Media Coverage News SentimentCidara Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for CDTX on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,755.00 in company stock.Percentage Held by InsidersOnly 7.64% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions.Read more about Cidara Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cidara Therapeutics are expected to decrease in the coming year, from ($12.06) to ($12.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cidara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. About Cidara Therapeutics Stock (NASDAQ:CDTX)Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Read More CDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDTX Stock News HeadlinesSeptember 14 at 9:11 AM | insidertrades.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells $10,755.36 in StockSeptember 16 at 2:58 AM | americanbankingnews.comCidara Therapeutics (NASDAQ:CDTX) Upgraded by StockNews.com to "Hold"September 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.September 14 at 8:08 AM | msn.comCidara axes 30% of staff to focus on flu prevention drugSeptember 13 at 1:56 AM | markets.businessinsider.comCidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock DownSeptember 12, 2024 | marketwatch.comCidara Therapeutics to Cut Workforce by 30%September 12, 2024 | globenewswire.comCidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388September 5, 2024 | globenewswire.comCidara to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 19, 2024 | globenewswire.comCidara Therapeutics Announces Appointment of Jim Beitel as Chief Business OfficerAugust 16, 2024 | msn.comHC Wainwright & Co. Upgrades Cidara Therapeutics (CDTX)August 14, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsJuly 3, 2024 | globenewswire.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | globenewswire.comCidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 ConferenceMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology PipelineMay 16, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 16, 2024 | msn.comCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024See More Headlines Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/16/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDTX CUSIPN/A CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$29.67 High Stock Price Target$40.00 Low Stock Price Target$24.00 Potential Upside/Downside+148.5%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,930,000.00 Net Margins-289.05% Pretax Margin-317.19% Return on Equity-109.89% Return on Assets-34.82% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio4.25 Sales & Book Value Annual Sales$63.90 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value($1.82) per share Price / Book-6.56Miscellaneous Outstanding Shares7,040,000Free Float4,213,000Market Cap$84.06 million OptionableOptionable Beta1.04 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jeffrey L. Stein Ph.D. (Age 69)President, CEO & Executive Director Comp: $603.7kMr. Shane M. Ward (Age 49)Chief Legal Officer,Corporate Secretary & COO Comp: $464.54kDr. Taylor Sandison M.D. (Age 52)M.P.H., Chief Medical Officer Comp: $497kDr. Kevin M. Forrest Ph.D. (Age 47)Founder and Chief Strategy Officer Comp: $333.31kDr. Preetam Shah M.B.A. (Age 51)Ph.D., CFO, Chief Business Officer & Principal Accounting Officer Comp: $577.85kMs. Allison Lewis CCPSPHR, Senior Vice President of People & CultureDr. Leslie Tari Ph.D. (Age 56)Chief Scientific Officer Comp: $845.1kMs. Laura A. NavaltaSenior Vice President of Clinical OperationsDr. Nicole Davarpanah J.D.M.D., Senior VP of Translational Research & DevelopmentMore ExecutivesKey CompetitorsNeon TherapeuticsNASDAQ:NTGNSCYNEXISNASDAQ:SCYXX4 PharmaceuticalsNASDAQ:XFORCurisNASDAQ:CRISApplied Genetic TechnologiesNASDAQ:AGTCView All CompetitorsInsiders & InstitutionsTaylor SandisonSold 924 sharesTotal: $10,755.36 ($11.64/share)Alethea Capital Management LLCSold 1,518,584 shares on 8/15/2024Ownership: 1.752%Renaissance Technologies LLCSold 2,459,456 shares on 8/9/2024Ownership: 2.094%Jeffrey SteinBought 8,000 shares on 6/7/2024Total: $105,680.00 ($13.21/share)Leslie TariSold 1,051 sharesTotal: $14,083.40 ($13.40/share)View All Insider TransactionsView All Institutional Transactions CDTX Stock Analysis - Frequently Asked Questions How have CDTX shares performed this year? Cidara Therapeutics' stock was trading at $15.88 at the beginning of 2024. Since then, CDTX shares have decreased by 27.0% and is now trading at $11.60. View the best growth stocks for 2024 here. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) released its earnings results on Tuesday, August, 13th. The biotechnology company reported ($2.05) earnings per share for the quarter, beating analysts' consensus estimates of ($3.94) by $1.89. The biotechnology company earned $0.30 million during the quarter. Cidara Therapeutics had a negative net margin of 289.05% and a negative trailing twelve-month return on equity of 109.89%. When did Cidara Therapeutics' stock split? Cidara Therapeutics shares reverse split on the morning of Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Cidara Therapeutics' top institutional shareholders include Renaissance Technologies LLC (2.09%) and Alethea Capital Management LLC (1.75%). Insiders that own company stock include Jeffrey Stein, Taylor Sandison, Leslie Tari, Preetam Shah, Paul Daruwala, Shane Ward and Brady Johnson. View institutional ownership trends. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU) and Exelixis (EXEL). This page (NASDAQ:CDTX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDTX Stock Alerts